Outlook Therapeutics, Inc. (OTLK) NASDAQ

1.62

+0.015(+0.94%)

Updated at July 01 12:28PM

Currency In USD

Outlook Therapeutics, Inc.

Address

Building F

Iselin, NJ 08852

United States of America

Phone

609 619 3990

Sector

Healthcare

Industry

Biotechnology

Employees

23

First IPO Date

June 14, 2016

Key Executives

NameTitlePayYear Born
Mr. Lawrence A. Kenyon CPAEVice President, Chief Financial Officer, Interim Chief Executive Officer, Treasurer, Secretary & Director476,1701966
Mr. Jeffrey EvansonChief Commercial Officer451,1701969
Dr. Surendra Sharma M.D.Senior Vice President of Medical Affairs0N/A
Dr. Jennifer M. Kissner Ph.D.Senior Vice President of Clinical Development & Regulatory Affairs0N/A
Mr. Joel PrieveSenior Vice President of Licensing and M&A0N/A
Mr. Jedd ComiskeySenior Vice President - Head of Europe0N/A

Description

Outlook Therapeutics, Inc., a late clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases. Outlook Therapeutics, Inc. has collaboration and license agreements with IPCA Laboratories Limited; Laboratorios Liomont, S.A. de C.V.; BioLexis Pte. Ltd.; and Zhejiang Huahai Pharmaceutical Co., Ltd. The company was formerly known as Oncobiologics, Inc. and changed its name to Outlook Therapeutics, Inc. in November 2018. Outlook Therapeutics, Inc. was incorporated in 2010 and is based in Iselin, New Jersey.